| Drug Name: | Erythromycin (114-07-8) |
|---|---|
| PubChem ID: | 12560 |
| SMILES: | CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O |
| InchiKey: | ULGZDMOVFRHVEP-RWJQBGPGSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents, Enzyme Inhibitors, Gastrointestinal Agents, Protein Synthesis Inhibitors |
| Molecular Weight (dalton) | : | 733.937 |
| LogP | : | 1.7856 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 14 |
| Hydrogen Bond Donor Count | : | 5 |
| Total Polar Surface Area | : | 193.91 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Disopyramide ((3737-09-5)) | Arrhythmia | Additive | Not fully established. An in vitro study using human liver microsomes indicated that erythromycin inhibits the metabolism (mono-N-dealkylation) of disopyramide which, in vivo, would be expected to reduce its loss from the body and increase its serum levels. | Potentially fatal interaction between erythromycin and disopyramide |
| Cimetidine (51481-61-9) | Deafness | Additive | Cimetidine is known to inhibit the N-demethylation of erythromycin so that it is metabolised and cleared from the body more slowly and its serum levels rise. Deafness is known to be one of the adverse effects of erythromycin, which usually occurs with high-doses or intravenous therapy, and was probably exacerbated by renal impairment | Erythromycin deafness and cimetidine treatment |
| Amiodarone (1951-25-3) | Torsade De Pointes | Additive | Amiodarone alone can prolong the QT interval and increase the risk of torsade de pointes. Intravenous erythromycin is known to prolong the QT interval. Amiodarone and erythromycin may therefore have additive effects on the QT interval | Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism |
| Carbimazole (22232-54-8) | Torsade De Pointes | Antagonistic | Intravenous erythromycin may cause QT prolongation and torsade de pointes. It is rare with oral erythromycin. Carbimazole is rapidly metabolised to thiamazole which is the active form of the drug. | Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration |
| Bromocriptine (25614-03-3) | Psychotic Behavior | Synergistic | Bromocriptine metabolise by the cytochrome P450 isoenzyme CYP3A4. Erythromycin inhibit this metabolism | Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine |
| Carbamazepine (298-46-4) | Diplopia | Synergistic | Erythromycin slow the rate of metabolism of the carbamazepine by the cytochrome P450 isoenzyme CYP3A4 | Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite |
| Terfenadine (50679-08-8) | Torsade De Pointes | Synergistic | macrolides ( erythromycin ) appear to reduce the metabolism of terfenadine by inhibition of the cytochrome P450 isoenzyme CYP3A | Oxidation of the antihistaminic drug terfenadine in human liver microsomes Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation |
| Quinidine (56-54-2) | Torsade De Pointes | Additive | Not fully understood, but erythromycin inhibits the metabolism of quinidine, possibly by inhibition of the cytochrome P450 isoenzyme CYP3A4, thereby reducing its clearance from the body and increasing its effects. Quinidine and erythromycin may have additive effects on the QT interval in addition to the pharmacokinetic interaction. | Possible inhibition of hepatic metabolism of quinidine by erythromycin |
| dihydroergotamine (6190-39-2) | Ischaemic Chest Pain | Synergistic | Erythromycin is potent inhibitors of the cytochrome P450 isoenzyme CYP3A4, an enzyme involved in the metabolism of ergot derivatives | Severe vascular spasm due to erythromycin-ergotamine interaction |
| Vinblastine (865-21-4) | Constipation | Synergistic | Uncertain | Vinblastine and erythromycin: an unrecognized serious drug interaction |
| Vinblastine (865-21-4) | Myalgia | Synergistic | Uncertain | Vinblastine and erythromycin: an unrecognized serious drug interaction |
| Vinblastine (865-21-4) | Myositis | Synergistic | Uncertain | Vinblastine and erythromycin: an unrecognized serious drug interaction |
| Vinblastine (865-21-4) | Neutropenia | Synergistic | Uncertain | Vinblastine and erythromycin: an unrecognized serious drug interaction |
| Valproic Acid (99-66-1) | Confusion | Synergistic | Unclear | Erythromycin and valproate interaction |
| Valproic Acid (99-66-1) | Slurred Speech | Synergistic | Unclear | Erythromycin and valproate interaction |
| Valproic Acid (99-66-1) | Worsening Gait | Synergistic | Unclear | Erythromycin and valproate interaction |
This panel provides drug-protein interaction and their ADRs along with references
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|---|---|
| Grapefruit Juice | Torsade De Pointes | Grapefruit-medication interactions: forbidden fruit or avoidable consequences? |
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category